Sermorelin Overview

Sermorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH 1-29). It is studied in laboratory and preclinical models for its ability to stimulate the release of endogenous growth hormone, thereby influencing IGF-1 production and associated signaling pathways. Research has focused on its role in endocrine regulation, cellular growth, and tissue repair processes.

Walker R.F. et al. (1994).

History

Sermorelin was developed in the late 20th century as a stabilized fragment of GHRH (1-29), the biologically active portion of the endogenous hormone. Initial investigations focused on its pharmacokinetics and ability to promote pituitary GH release. Since then, it has been used widely in experimental models to study endocrine dynamics, tissue recovery, and age-related changes in growth hormone signaling.

Walker R.F., Risher W.H. et al. (1994).

Sermorelin Structure

CAS #: 86168-78-7

Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S

Molecular Weight: 3357.9 g/mol

PubChem ID: 16132308

Research Findings

Sermorelin has been investigated in endocrine, metabolic, and regenerative models, with research focusing on its ability to stimulate growth hormone release, modulate IGF-1 activity, and support tissue repair mechanisms. Studies also highlight its role in metabolic regulation, cellular proliferation, and recovery processes in preclinical settings.

Key Areas of Research:

• Endocrine: GH release, IGF-1 activity, signaling

• Metabolic: lipid, glucose, insulin sensitivity

• Cellular: proliferation, repair, protein synthesis

Together, these findings suggest experimental utility for Sermorelin across multiple biological systems. By engaging growth hormone pathways and influencing metabolic and regenerative processes, Sermorelin provides a platform for research into tissue repair, cellular recovery, and endocrine regulation in laboratory models.

Walker R.F. et al., 1994

References

Walker R.F. et al. (1994). Pharmacokinetics and biological activity of Sermorelin, a GHRH analog, in preclinical models. Metabolism, 43(6): 781–786.

Corpas E. et al. (1992). Endocrine and metabolic effects of Sermorelin in research studies. J Clin Endocrinol Metab, 75(6): 1523–1528.